Keros Therapeutics, Inc.

Keros Therapeutics, Inc.verified

KROS

Price:

$10.15

Market Cap:

$324.78M

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in...[Read more]

Industry

Biotechnology

IPO Date

2020-04-08

Stock Exchange

NASDAQ

Ticker

KROS

The Current Ratio as of June 2026 (TTM) for Keros Therapeutics, Inc. (KROS) is 22.62

According to Keros Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 22.62. This represents a change of 1.60% compared to the average of 22.26 of the last 4 quarters.

Keros Therapeutics, Inc. (KROS) Historical Current Ratio (quarterly & annually)

How has KROS Current Ratio performed in the past?

The mean historical Current Ratio of Keros Therapeutics, Inc. over the last ten years is 16.39. The current 22.62 Current Ratio has changed 13.70% with respect to the historical average. Over the past ten years (40 quarters), KROS's Current Ratio was at its highest in in the December 2020 quarter at 37.27. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Quarterly (TTM)
Annual

Average

16.39

Median

16.36

Minimum

1.99

Maximum

37.27

Keros Therapeutics, Inc. (KROS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Keros Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.77%

Maximum Annual Current Ratio = 37.27

Minimum Annual Increase = -43.04%

Minimum Annual Current Ratio = 1.99

Quarterly (TTM)
Annual
YearCurrent RatioChange
202515.45-27.97%
202421.4550.56%
202314.25-17.49%
202217.27-18.64%
202121.23-43.04%
202037.271.77%
20191.99-10.61%

Keros Therapeutics, Inc. (KROS) Average Current Ratio

How has KROS Current Ratio performed in the past?

The current Current Ratio of Keros Therapeutics, Inc. (KROS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

17.05

5-year avg

17.93

10-year avg

16.39

Keros Therapeutics, Inc. (KROS) Current Ratio vs. Peers

How is KROS’s Current Ratio compared to its peers?

Keros Therapeutics, Inc.’s Current Ratio is greater than REGENXBIO Inc. (2.62), greater than Verastem, Inc. (3.04), greater than Absci Corporation (6.59), greater than Niagen Bioscience Inc (4.61), greater than CytomX Therapeutics, Inc. (10.38), greater than Ventyx Biosciences, Inc. (17.86), greater than MoonLake Immunotherapeutics (8.60), greater than Corvus Pharmaceuticals, Inc. (19.81), greater than Olema Pharmaceuticals, Inc. (10.88), greater than Rigel Pharmaceuticals, Inc. (2.62),

Build a custom stock screener for Keros Therapeutics, Inc. (KROS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keros Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Keros Therapeutics, Inc. (KROS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Keros Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Keros Therapeutics, Inc.'s Current Ratio?

How is the Current Ratio calculated for Keros Therapeutics, Inc. (KROS)?

What is the highest Current Ratio for Keros Therapeutics, Inc. (KROS)?

What is the 3-year average Current Ratio for Keros Therapeutics, Inc. (KROS)?

What is the 5-year average Current Ratio for Keros Therapeutics, Inc. (KROS)?

How does the current Current Ratio for Keros Therapeutics, Inc. (KROS) compare to its historical average?